predicative of response 3 . One of the most studied miRs, miR-155 and its host gene BIC, have been previously indicated to be overexpressed in CLL and has been found to be leukemogeneic when overexpressed under a B cell specific promoter in mice 4, 5 . To further elucidate the clinical impact of baseline miR-155 expression, we examined clinical outcome of previously untreated patients treated with chemoimmunotherapy. A previous study using the CLL MEC1 cell line demonstrated targeting miR-155 lead to inhibition of proliferation 6 . miR-155 is critical for B cell development and can be enhanced by antigen receptor stimulation 7, 8 . miR-155 has been found to be up-regulated in B cell receptor (BCR) stimulated B cells. Also increased miR-155 expression has been linked to a BCR activated phenotype characterized by un-mutated IGVH and high ZAP70 expression 2, 7, 8, 9 . Given the relationship of between active BCR signaling and miR-155 expression, we examined the influence of the BCR targeted therapy, Bruton's tyrosine kinase inhibitor, ibrutinib, on expression of this onco-miR in vivo among patients at different time points during their treatment.
miR-155 expression in 109 patients who had been previously treated with fludarabine and rituximab (CALGB 9712) or fludarabine and rituximab followed by alemtuzumab (CALGB 10101) was measured 10, 11 . Baseline samples were procured from these patients and miR-155 analysis was done by Nanostring Technologies' nCounter platform. miR-155 levels were background corrected, normalized by quantile normalization, and the log(2) expression values for each patient were calculated. Nanostring analysis showed the expression of miR-155 was above the background threshold in all patients. Patients were dichotomized as high (n=53) and low expressers (n=56) using the median value of miR-155 expression (median intensity = 1154; range: 110-3265). The expression of miR-155 was not significantly associated with the majority of baseline demographic, clinical and cytogenetic characteristics, including age, Rai stage and high-risk cytogenetics del(17p)/del(11q) (all p>0.15). However, high miR-155 expression was significantly associated with IGHV unmutated disease (p=0.03) and ZAP70 methylation <20% (p<0.001). Among the high miR-155 expressers, 81% had IGHV un-mutated disease and 94% had low ZAP70 methylation, compared to low miR-155 expressers with 58% IGHV un-mutated disease and 65% with low ZAP70 methylation. With respect to clinical outcome, patients with high miR-155 expression had a significantly shorter progression free survival (PFS) (p=0.005) and tended toward shorter overall survival (OS) (p=0.06) compared to those with low miR-155 expression ( Figures 1A-B) . The high miR-155 expressers had an estimated median PFS of 29 months (95% CI: 20-35) and an OS of 71 months (95% CI: 63-91), respectively, versus low expresser with an estimated median PFS 42 months (95% CI: 29-51) and OS of 88 months (95% CI: 67-not reached). In a multivariable model for PFS, high miR-155 remained significantly associated with higher risk of relapse or death (HR=1.82, 95% CI: 1.13-2.94, p=0.01) when adjusting for high-risk cytogenetics and increased WBC. For OS, there was evidence of non-proportional hazards, where the risk of death increased with longer follow-up. In a model adjusting for hemoglobin, the risk of death in the first 4 years on study was not significantly different according to miR-155 expression (HR=0.95, 95% CI: 0.41-2.19, p=0.91), but thereafter, higher miR-155 expression was associated with increased risk of death (HR=3.25, 95% CI: 1.46-7.21, p=0.004).
Given the potential oncogenic role of miR-155 and contribution of its over-expression to shortened PFS and OS with chemoimmunotherapy in CLL, we next sought to determine if this could be therapeutically targeted. The BCR activated phenotype is known to be closely associated with patients with poor prognostic factors, such as high ZAP70 expression and un-mutated IGHV status 9 . Associations between miR-155 expression, ZAP70 expression and IGHV mutational status and BCR activation have been made in recent literature 2, 12 . It has been observed that CLL patients with high miR-155 are generally more responsive to BCR ligation, showing a greater amount of anti-μ induced calcium flux, compared to patients with low miR-155 12 . The distinct relationship between BCR activation and miR-155 led to the hypothesis that BCR targeted therapies could potentially modulate miR-155 expression. Ibrutinib, an irreversible inhibitor, which binds cysteine 481 of Bruton's tyrosine kinase (BTK) has been previously shown to decrease pro-survival signaling, such as AKT, ERK and NFκB 13 . BTK has been found to be an integral kinase in the BCR pathway and important to the development and survival of leukemic B cells in the Eμ-TCL1 mouse model and also in in vitro analysis of primary CLL cells 14 . Ibrutinib has also been shown to be highly effective as a treatment in relapsed or refractory CLL 15 . It was found that patients with un-mutated IGHV disease, who are likely to have greater dependence on BCR stimulation, were found to clear their lymphocytosis earlier and meet traditional criteria for response 15 . While multiple BCR targeted genes were shown to be decreased by ibrutinib, the influence on miR-155 expression was not examined.
To investigate the close association between B cell receptor activation and miR-155 in CLL, we explored regulation of BCR pathways through ibrutinib inhibition of BTK and its ability to modulate miR-155. We initially examined blood samples from 12 CLL patients prior to receiving ibrutinib (420mg/day) and after 1 week (C1D8) and 29 days (C2D1) with treatment on OSU-10053 16 . RNA was extracted using the Trizol and purified with the miRVana kit (Ambion). miR-155 expression was assessed by quantitative real time PCR (RT-PCR). Quantitative RTPCR expression was normalized to housekeeping gene RNU44 using the 2 -ΔCT method and fold changes found by normalizing each patient's C1D8 and C2D1 values relative to the pre-treatment value are presented. Analysis by t-tests using mixed effects models to account for repeated measures over time showed significantly down-regulated miR-155 expression at C1D8 (p< 0.001) and C2D1 (p=0.001) relative to baseline (Figure 2A) . To confirm this, we examined lymphocytes from 34 additional patients treated with ibrutinib on OSU-11133 (NCT01589302), and found that on average, miR-155 expression post-treatment with ibrutinib was 0.71 times the expression prior to therapy (95% CI: 0.59-0.85, p=0.0006; Figure 2B ) 17 . miR-155 expression was downregulated at C2D1 in 29 (85%) of the patients studied.
The response pattern observed with ibrutinib includes traditional partial and complete responses, but also patients who have dramatic node disease reduction but persistent blood lymphocytosis that remains asymptomatic for an extended period of time without evidence of active proliferation 18 . In contrast, patients who relapse after responding to ibrutinib typically have proliferative disease 19 . Expression of miR-155 was measured in serial samples from patients with a partial response with persistent lymphocytosis at 1 year as well as in patients responding to ibrutinib with subsequent progressions to determine if expression patterns were similar or different. In patients with lymphocytosis, miR-155 expression decreased with 29 days of ibrutinib treatment and remained at this lower expression level at 1 year relative to baseline (p=0.013; Figure 2C ). In contrast, patients who relapsed with ibrutinib treatment showed elevated miR-155 expression relative to baseline (p=0.002; Figure 2D ), despite an initial decrease in expression with response.
Herein, we provide the evidence indicating that miR-155 is predictive of outcome in CLL patients treated with frontline chemoimmunotherapy, independent of high-risk cytogenetic abnormalities and common clinical characteristics. We also demonstrate that high miR-155 expression correlates with low ZAP70 methylation and confirm the finding of others relative to its association with un-mutated IGHV disease. Our findings further associate BCR regulation with the expression of miR-155 by demonstrating that the irreversible BTK inhibitor ibrutinib treatment can down-regulate miR-155 within the first cycle of therapy. For patients without progression, including those with partial response with peripheral lymphocytosis, the down-modulation is persistent. In contrast, those patients that progress on ibrutinib therapy do not maintain miR-155 down-regulation. The relevance of our findings are significant as they use cellular miR-155 levels to risk stratify CLL patients receiving chemoimmunotherapy and also identify an effective therapeutic, ibrutinib, which targets the critical BCR signaling pathway, which can down modulate a leukemogenic miR. A. Kaplan-Meier curves of progression-free survival according to low and high levels of miR-155 expression in relapse/refractory CLL patients prior to treatment with chemoimmunotherapy B. Kaplan-Meier curves of overall survival according to low and high levels of miR-155 expression in relapse/refractory CLL patients prior to treatment with chemoimmunotherapy. Guinn A. miR-155 expression at pre-ibrutinib treatment. miR-155 down-modulation at 8 days (C1D8) (p<0.0001), and 29 days (C2D1) (p=0.001) of treatment with ibrutinib. B. miR-155 expression at pre-treatment and 29 days (C2D1) of treatment with ibrutinib; miR-155 expression was significantly down-regulated at C2D1 (p=0.0006) relative to pre-treatment. n=34 C. miR-155 expression in patients with a partial response with persistent blood lymphocytosis: at pre-treatment, 29 days (C2D1) and 1 year (C12D1) of therapy n=5; miR-155 expression was significantly decreased at C2D1 (p=0.005) and at C12D1 (p=0.013) relative to pre-treatment. D. miR-155 expression in ibrutinib relapse patients: at pre-treatment, time of response, and time of relapse n=4; miR-155 expression was significantly decreased at time of response (p=0.002) but significantly increased at relapse (p=0.002) relative to pre-treatment.
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